Zymeworks Inc Common Stock

Yahoo Finance • 23 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.2% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 23 days ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • last month

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • last month

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Zymeworks sees revenue surge in Q2 2025

Zymeworks Inc. reported a significant increase in revenue for the second quarter of 2025, achieving $48.7 million compared to $19.2 million in the same period last year. This growth was driven by key milestone payments and deferred revenue... Full story

Yahoo Finance • 2 months ago

Zymeworks GAAP EPS of $0.03 beats by $0.52, revenue of $48.7M beats by $31.52M

* Zymeworks press release [https://seekingalpha.com/pr/20194039-zymeworks-provides-corporate-update-and-reports-second-quarter-2025-financial-results] (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]): Q2 GAAP EPS of $0.03 beats by $0... Full story

Yahoo Finance • 2 months ago

Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance

[Human liver cancer concept, liver cirrhosis] * The U.S. FDA has cleared an Investigational new drug application (IND) for Zymeworks' (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]) ZW251, an antibody-drug conjugate for the treatme... Full story

Yahoo Finance • 2 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favorable tolerability profilePhase 1 clinica... Full story

Yahoo Finance • 2 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 3 months ago

Zymeworks stock holds steady as H.C. Wainwright reiterates Neutral rating

Investing.com - H.C. Wainwright has reiterated its Neutral rating and $13.00 price target on Zymeworks (NASDAQ:ZYME) following recent developments with its zanidatamab therapy. The company, currently trading near $12.89, has delivered an i... Full story

Yahoo Finance • 4 months ago

Zymeworks gets China's conditional approval for biliary tract cancer treatment

[Cancer cells vis] koto_feja/E+ via Getty Images * Zymeworks (NASDAQ:ZYME [https://seekingalpha.com/symbol/ZYME]) said on Friday that the China health regulator has given conditional approval to zanidatamab for the treatment of metastat... Full story

Yahoo Finance • 4 months ago

Zymeworks Gets China's NMPA Approval For Zanidatamab

(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biotechnology company, Friday said that the National Medical Products Administration (NMPA) in China has approved zanidatamab for the treatment of HER2-high expression (IHC3+) biliary tra... Full story

Yahoo Finance • 4 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study$20 million milestone payment to be re... Full story

Yahoo Finance • 4 months ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to... Full story

Yahoo Finance • 4 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel bispecific design shows promising poten... Full story

Yahoo Finance • 5 months ago

Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...

Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zymeworks Inc (NASDAQ:ZYME) reported a significant increase in revenue for Q1 2025, reaching... Full story

Yahoo Finance • 5 months ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 5 months ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... Full story

Yahoo Finance • 6 months ago

Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zymeworks Inc. (NASDAQ:ZYME) stands against other stocks that insiders bought in April a... Full story

Yahoo Finance • 6 months ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favo... Full story